SALVATORE, LISA
 Distribuzione geografica
Continente #
NA - Nord America 1.136
EU - Europa 423
AS - Asia 156
AF - Africa 37
OC - Oceania 1
Totale 1.753
Nazione #
US - Stati Uniti d'America 1.111
IT - Italia 117
DE - Germania 85
SE - Svezia 70
CN - Cina 66
SG - Singapore 54
BG - Bulgaria 46
GB - Regno Unito 30
CA - Canada 25
FR - Francia 23
VN - Vietnam 21
AT - Austria 18
SN - Senegal 16
CI - Costa d'Avorio 13
FI - Finlandia 11
NG - Nigeria 8
RU - Federazione Russa 8
IN - India 6
UA - Ucraina 5
HK - Hong Kong 4
CH - Svizzera 2
JP - Giappone 2
NL - Olanda 2
NO - Norvegia 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
EE - Estonia 1
IL - Israele 1
KR - Corea 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 1.753
Città #
Woodbridge 231
Fairfield 149
Ashburn 93
Chandler 80
Seattle 71
Houston 69
Cambridge 59
Ann Arbor 51
Wilmington 48
Sofia 46
New York 36
Beijing 30
Pisa 26
Princeton 23
Lawrence 18
Ottawa 18
Vienna 18
Des Moines 17
Dakar 16
Medford 16
Singapore 16
Bremen 14
Abidjan 13
Dong Ket 13
Dearborn 12
London 12
Marseille 12
Florence 11
Redwood City 9
Lagos 8
Düsseldorf 7
Nanjing 7
Lancaster 6
Phoenix 6
Seacroft 6
Serra 6
Changsha 5
Kunming 5
Positano 5
San Diego 5
Boulder 4
Frankfurt am Main 4
Hong Kong 4
Lusciano 4
Polverigi 4
San Francisco 4
Shenyang 4
Toronto 4
Turin 4
Hebei 3
Leawood 3
Nürnberg 3
Ogden 3
Rome 3
Genoa 2
Guangzhou 2
Lecce 2
Los Angeles 2
Nanchang 2
Oslo 2
San Giuliano Terme 2
Tianjin 2
Aprilia 1
Berlin 1
Bern 1
Bracknell 1
Bratislava 1
Buffalo 1
Capannori 1
Capurso 1
Chengdu 1
Chiswick 1
Council Bluffs 1
Cutrofiano 1
Duncan 1
Esslingen am Neckar 1
Fuzhou 1
Gallarate 1
Geneve 1
Genova 1
Grafing 1
Haifa 1
Hamilton 1
Hangzhou 1
Hefei 1
Helsinki 1
Indiana 1
Indore 1
Jinan 1
Jüchen 1
Kent 1
Kyiv 1
Leipzig 1
Markham 1
Melbourne 1
Milan 1
Montreal 1
Mumbai 1
Norwalk 1
Oakville 1
Totale 1.398
Nome #
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 145
TAS-102 for the treatment of metastatic colorectal cancer 131
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 130
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 116
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 110
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 109
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 106
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 102
null 98
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 96
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 89
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 87
null 85
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 73
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 73
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 73
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 59
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 42
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 24
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 20
First-line chemotherapy for mCRC-a review and evidence-based algorithm 15
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 15
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 13
Totale 1.811
Categoria #
all - tutte 5.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.345


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020425 42 33 9 35 61 60 45 38 41 27 23 11
2020/2021162 10 9 5 12 13 5 9 6 40 11 19 23
2021/2022214 3 9 2 3 34 36 4 5 19 13 9 77
2022/2023303 24 48 20 34 31 35 2 14 72 2 18 3
2023/2024179 14 12 26 8 23 28 16 17 4 3 8 20
Totale 1.811